Last reviewed · How we verify
Oxygen 30 %
At a glance
| Generic name | Oxygen 30 % |
|---|---|
| Sponsor | Negovsky Reanimatology Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Optimization of Exhaled Biomarker Collection and Analysis (NA)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- Diaphragmatic Physiology Similarity Index May Titrate HFNC Flow Setting: A Prospective Observational Study (NA)
- Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment (NA)
- Camel Milk Impact on Aerobic Exercise Recovery, Induced Inflammation, and Physical Performance (NA)
- Impact of the Early Life Virome Development on Bronchopulmonary Dysplasia in Preterm Neonates
- Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |